Both ours and the mentioned previous study [31,32,34,35] suggest that there is an urgent need to develop galectin-3 inhibitors that have a high oral bioavailability and a low toxicity profile to combat increased galectin-3 levels which are related with the developing HF in DM. Here, LGALS3 is linked to diabetes mellitus.